Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-08-24FDA Approved: FOSPHENYTOIN SODIUM — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for fosphenytoin sodium submitted by Amneal Pharmaceuticals LLC.
-
FDA approval · 2022-08-22FDA Approved: CARBAMAZEPINE — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved the Original Application for generic carbamazepine from Unichem Pharmaceuticals (USA), Inc.
-
FDA approval · 2022-08-18FDA Approved: CARBAMAZEPINE — Original Application (Northstar Rx LLC)
FDA approved the original generic application for Carbamazepine from Northstar Rx LLC, authorizing a generic version of the anticonvulsant. …
-
FDA approval · 2022-08-16FDA Approved: ETHOSUXIMIDE — Supplemental Application (Epic Pharma, LLC)
FDA approved a supplemental application for Ethosuximide filed by Epic Pharma, LLC.
-
FDA approval · 2022-08-08FDA Approved: VIGADRONE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for Vigadrone (vigabatrin) from Upsher-Smith Laboratories, LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2022-08-04FDA Approved: OXCARBAZEPINE — Supplemental Application (Advagen Pharma Limited)
The FDA issued a supplemental approval for oxcarbazepine by Advagen Pharma Limited, resulting in changes to the product's labeling.
-
FDA approval · 2022-07-27FDA Approved: LAMOTRIGINE — Supplemental Application (Alembic Pharmaceuticals Limited)
The FDA approved a supplemental application for the lamotrigine generic product from Alembic Pharmaceuticals Limited, reflecting a regulator…
-
FDA approval · 2022-07-26FDA Approved: ACETAZOLAMIDE — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for acetazolamide filed by Strides Pharma Science Limited, authorizing an update to the generic prod…
-
FDA approval · 2022-07-20FDA Approved: LEVETIRACETAM EXTENDED-RELEASE — Supplemental Application (Omnivium Pharmaceuticals LLC)
The FDA approved a supplemental application to authorize an extended-release formulation of levetiracetam, manufactured by Omnivium Pharmace…
-
FDA approval · 2022-07-18FDA Approved: LAMOTRIGINE — Supplemental Application (Jubilant Cadista Pharmacuticals Inc.)
The FDA approved a supplemental application for a generic lamotrigine product from Jubilant Cadista Pharmaceuticals Inc.
-
FDA approval · 2022-07-15FDA Approved: ZONISADE — Original Application (Azurity Pharmaceuticals, Inc.)
FDA approved ZONISADE (zonisamide) via an original NDA for use in epilepsy, including partial-onset seizures.
-
FDA approval · 2022-07-15FDA Approved: LEVETIRACETAM — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approves a supplemental application for levetiracetam from Amneal Pharmaceuticals LLC, authorizing generic production and distributi…
-
FDA approval · 2022-07-15FDA Approved: LEVETIRACETAM — Original Application (Novadoz Pharmaceuticals LLC)
FDA approves Novadoz's original ANDA for Levetiracetam, establishing a generic anti-seizure medication. Indications include epilepsy-related…
-
FDA approval · 2022-07-08FDA Approved: LAMOTRIGINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Lamotrigine by Aurobindo Pharma Limited, enabling a generic lamotrigine product.
-
FDA approval · 2022-06-30FDA Approved: LAMOTRIGINE KIT — Supplemental Application (OWP Pharmaceuticals, Inc.)
FDA approved a supplemental application for the Lamotrigine Kit from OWP Pharmaceuticals, authorizing the lamotrigine kit formulation.
-
FDA approval · 2022-06-29FDA Approved: LACOSAMIDE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved lacosamide via an original generic application (ANDA) for Zydus Pharmaceuticals USA Inc.
-
FDA approval · 2022-06-28FDA Approved: PRIMIDONE — Original Application (Advagen Pharma Limited)
FDA approved the original Abbreviated New Drug Application for PRIMIDONE (Primidone) from Advagen Pharma Limited.
-
FDA approval · 2022-06-27FDA Approved: XCOPRI — Supplemental Application (SK Life Science, Inc.)
The FDA approved a supplemental application for XCOPRI (cenobamate) from SK Life Science, expanding its label for seizure indications.
-
FDA approval · 2022-06-17FDA Approved: LEVETIRACETAM — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application from Amneal Pharmaceuticals LLC to market a generic version of Levetiracetam.
-
FDA approval · 2022-06-16FDA Approved: CLORAZEPATE DIPOTASSIUM — Original Application (ANI Pharmaceuticals, Inc.)
FDA approved ANI Pharmaceuticals' original application for a generic clorazepate dipotassium product.
-
FDA approval · 2022-06-10FDA Approved: LAMOTRIGINE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Lamotrigine from Zydus Pharmaceuticals USA Inc., indicating a post-approval modification to …
-
FDA label_change · 2022-06-10FDA Approved: LAMOTRIGINE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Lamotrigine from Zydus Pharmaceuticals USA Inc., signaling a labeling change or addition to …
-
FDA approval · 2022-06-09FDA Approved: BRIVARACETAM — Original Application (SolarisPharmaCorporation)
FDA approved an abbreviated new drug application for brivaracetam (generic) by SolarisPharmaCorporation under ANDA214748, enabling a generic…
-
CLINICAL_TRIALS trial_result · 2022-06-02Clinical Trial Update: Outcomes Mandate National Integration With Cannabis as Medicine [Phase 2]
Phase 2 clinical trial update focusing on integrating cannabis as medicine for various chronic pain conditions, with status currently UNKNOW…
-
FDA approval · 2022-05-31FDA Approved: LACOSAMIDE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' original application for lacosamide, enabling a generic lacosamide product to enter the market.